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[6]). The acetyl groups facilitate entry of the drug into
cells, but once FK317 has crossed the membrane barrier
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difference between it and FR900482 (see Discussion;2 Department of Chemistry
Colorado State University Figure 1). Without the acetyl groups FK317 cannot be
transported out of the cell by P-glycoprotein (commonlyFort Collins, Colorado 80523
referred to as the multidrug resistance channel), thus
leading to increased intracellular concentrations of the
drug [8]. Both FR900482 and FK317 are prodrugs thatSummary
are reductively activated inside cells. This activation oc-
curs preferentially in the hypoxic microenvironment ofVascular leak syndrome (VLS) is a harmful side effect
that resulted in withdrawal of the antitumor drug solid tumors, and it is thought to proceed through a
mitosene intermediate structurally similar to that formedFR900482, but not FK317, from clinical trials. Here we
present chromatin immunoprecipitation data showing by the reductive activation of mitomycin C [9–11]. In the
reductive environment of tumor cells, FK317 is metabo-that FK317, like FR900482, crosslinks minor-groove
binding proteins to DNA in vivo. However, these drugs lized to the corresponding C12 alcohol derivative
FR160516. This metabolite subsequently suffers a thiol-differ in how they induce cell death. We demonstrate
that, whereas FR900482 induces necrosis, FK317 in- mediated two-electron reduction of the N-O bond to
the azocine ring system, which rapidly cyclizes to theduces a necrosis-to-apoptosis switch that is drug con-
centration dependent. Northern blot analyses of drug- carbinolamine which, after expulsion of water, produces
a highly reactive electrophilic mitosene derivative [12].treated cells suggest that this “switch” is mediated,
at least in part, by modulation of the expression levels In contrast, in nontumorogenic cells, FK317 is metabo-
lized to the C12 carboxylic acid derivative that lacksof Bcl-2. Additionally, FR900482, in contrast to FK317,
induces the expression of known elicitors of both Bcl-2 chemotherapeutic activity [6].
It is therefore important, not only from a drug designgene expression and VLS. These findings provide plau-
sible explanations for why these structurally similar point of view but also from a biochemical perspective, to
understand why two drugs of almost identical structuredrugs have different biological effects, especially with
respect to VLS. have such different biological effects with respect to
induction of VLS and, consequently, have such different
potentials as effective anticancer agents. Evidence pre-Introduction
sented here suggests that differences in the mode of
action of the two drugs in inducing cell death and/or inThe mitosene-based antitumor drugs FR900482 and
FK317 have markedly different biological side effects inducing transcriptional expression of the IL-2 gene, a
known contributor to VLS, might be significant compo-even though they have very similar chemical structures
(Figure 1). Specifically, the FR900482 drug induces vas- nents in their differential biological effects.
cular leak syndrome (VLS), whereas its semisynthetic
derivative FK317 does not. As a consequence, FK317
Results and Discussionis currently in phase II clinical trials for cancer treatment
in Japan as a possible new chemotherapeutic agent to
Cell Growth Inhibition and Toxicity Studiespotentially replace the now widely used drug mitomycin
We have previously reported the effects of the FR900482C. VLS is characterized by an increase in vascular per-
drug on the growth inhibition and toxicity of the humanmeability that leads to increased leakage of fluids into
Jurkat acute T cell leukemia line [13]. To directly com-interstitial spaces; this leakage results in peripheral
pare the effects of the FK317 drug with those ofedema and, ultimately, organ failure [1–3]. Additional
FR900482, we subcultured Jurkat cells and allowedVLS symptoms include weight gain, hypoalbuminemia,
them to grow for 24 hr before adding various concentra-pleural and pericardical infusion, and pulmonary and
tions (0, 0.5, 1.0, and 1.5 M) of FK317 to the mediumcardiovascular failure [3]. VLS has been linked to expo-
(Figure 2). Cell number and viability were then deter-sure to immunotoxins such as ricin A and to treatment
mined every 24 hr for the next 72 hr. As expected, awith high concentrations of cytokines such as interleu-
concentration-dependent effect of FK317 on cell growthkin-2 (IL-2), as well as to various pathological conditions
(as determined by counting cell numbers) was observedsuch as T cell lymphoma, sepsis, trauma, and burns [1,
with 0.5 M of the drug being quite inhibitory to growth2, 4, 5].
and with both 1.0 and 1.5 M concentrations stoppingThe semisynthetic FK317 drug is chemically modified
growth all together (Figure 2). Furthermore, as discussed
later, Jurkat cells treated with much higher concentra-3 Correspondence: reevesr@wsu.edu (R.R.); rmw@chem.colostate.
edu (R.M.W.) tions of FK317 (10 and 100 M) also stopped cell growth
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Figure 1. Chemical Structures of FK317 and
FR900482
Positions at which the two structures differ
are shown in bold.
within 24 hr of drug exposure. When Trypan Blue dye Protein-DNA Crosslinking Studies
A number of studies have indicated that the non-histone(2%) exclusion was used for monitoring cell viability, it
was again found, as anticipated, that FK317 exhibited protein HMGA1 (formerly named HMG-I/Y; [15]), to-
gether with other transcription factors such as NF-Ba concentration-dependent effect on viability (Table 1).
Interestingly, as shown in Table 1, even after 24 hr treat- and members of the Ets family (e.g., Elf-1), are involved
with the in vivo transcriptional regulation of the humanment with 1.5 M of the drug (i.e., at 48 hr after initiation
of the experiment), an appreciable percentage of the IL-2 and IL-2R genes as a consequence of binding to
specific regions of their promoters [16–18]. Previously,cells in the population (85%) was still viable even
though these cells were not dividing (c.f., Figure 1). Nev- we have shown that treatment of Jurkat cells with
FR900482 crosslinks minor-groove binding proteinsertheless, after longer periods of drug treatment the
viability of the cells dramatically dropped to low levels such as HMGA1, HMGB1 (formerly HMG-1) and HMGB2
(formerly HMG-2) (but not major-groove binding proteinsregardless of the concentration. For example, after 72
hr treatment with 1.0 M of FK317 (i.e., 96 hr after initia- such as NF-B or Elf-1) to the promoter regions of the
IL-2 and IL-2R genes in vivo [13]. To determine whethertion of the experiment; Table 1), only about 4% of the
cells were still alive as judged by this dye exclusion FK317 also makes comparable protein-DNA minor-
groove crosslinks, we performed chromatin immuno-assay. When these results are compared with our previ-
ous findings for the effects of various concentrations of preciptation (ChIP) assays (see Experimental Proce-
dures for details) on Jurkat cells that had been treatedthe FR900482 drug on the same cells [13], it is obvious
that FK317 is considerably more toxic to Jurkat cells. with 0.5 M of FK317 for 24 hr (i.e., 48 hr after initiation
of the experiment, when 90% of the cells were stillSpecifically, a comparison of our previous results with
those reported here indicates that 0.5 M of FK317 viable; Table 1). In each ChIP experiment, parallel cul-
tures of untreated Jurkat cells, or untreated cells thatcauses as much inhibition of cell growth as does 1 M
of the FR900482 drug. Perhaps more importantly, after were fixed with 1% formaldehyde (a nonspecific cross-
linker) for 30 min, served as controls. Both the ex-72 hr of treatment with 1.0 M of FK317, less than 5%
of the cells are still viable (Table 1), whereas after the perimental and control cells were then disrupted by
sonication, and the resulting cellular extracts were im-same length of treatment with 1.0M of FR900482, more
than 90% of Jurkat cells are still viable [13]. Thus, in munopreciptated with specific antibodies against the
HMGA1, NF-B, or Elf-1 protein. After treatment to re-terms of cytotoxicity, FK317 appears to be a potentially
more effective chemotherapeutic agent than FR900482. verse any chemical crosslinks present in the immuno-
precipitates, PCR primers corresponding IL-2 and IL-The difference in cellular potency may, in part, be a
consequence of the two acetyl groups present on 2R promotor regions that are reportedly bound by the
HMGA1, Elf-1, or NF-kB protein in vivo were used toFK317, which may help this drug cross the cell mem-
brane more efficiently than FR900482 [14], and the sub- amplify DNA fragments present in the antibody com-
plexes. In ChIP assays, the production of PCR productssequent loss of the acetyl groups within the cell pre-
venting the expulsion of the drug back out of the cell [8]. indicates that the original cellular DNA template that has
Figure 2. Growth Curves of Jurkat Cells
Treated with Various Concentrations of the
FK317 Drug
Jurkat cells were treated with 0, 0.5, 1.0, or
1.5 M FK317. The number of cells in the
various cultures was manually determined by
hemocytometer counting. The arrow indi-
cates the point at which the drug was added
to cultures (i.e., at 24 hr after subculturing of
the cells).
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promoter regions of the IL-2R (panel A) and IL-2 (panelTable 1. Viability of Jurkat Cells Treated with Various
Concentrations of the FK317 Drug According to the Protocol B) genes in Jurkat cells treated with, or without, 0.5
Shown in Figure 2 M of FK317. The presence of specific amplified DNA
products in the immunoprecipitates of these ChIPPercent Viability
assays demonstrated that both the nonspecific chemi-
Hr Untreated 0.5 M 1 m 1.5 m
cal crosslinking reagent formaldehyde (lane 2; panels A
0 100 100 100 100 and B) and the drug FK317 (lane 3; panels A and B)
24 100 100 100 100 crosslinked the HMGA1 protein to the promoter regions
48 98.65 93.2725 90.34 85.83 of the IL-2 and IL-2R genes in Jurkat cells. The results
72 98.385 40.7575 18.6225 11.305
of several control experiments performed in parallel con-96 92.86 14.645 4.33 3.91
firmed the specificity of these ChIP reactions. These
Cellular viability was determined by the trypan blue dye (2%) exclu- controls produced the following results: (1) identical
sion assay.
ChiP assays performed on cells that had not been
treated with either the drug or formaldehyde showed
no amplification of either IL-2 or IL-2R gene promoter
undergone amplification was crosslinked in vivo to the fragments (lane 4; panels A and B); and (2) PCR reactions
protein recognized by the antibody as a consequence demonstrated that specific IL-2 (panel C) and IL-2R
of either direct protein-DNA or indirect protein-protein- (data not shown) promoter fragments could be amplified
DNA interactions. In the case of FK317- and FR900482- from the supernatants of all of the immunoprecipitation
treated cells, indirect protein-protein-DNA crosslinks reactions, indicating that there was ample DNA in the
are unlikely because both drugs have been shown to initial cell extracts for successful ChIP assays. Addi-
preferentially react with 5CpG-3 sites in the minor tional control ChIP experiments employing antibodies
groove of DNA [19]. The PCR products detected in the to DNA major-groove binding proteins (e.g., Elf-1 and
ChIP assays therefore probably result when the drugs NF-B) also demonstrated that specific PCR products
directly crosslink minor-groove proteins to cellular DNA. were not amplified from Jurkat cells treated (or not)
Figure 3 shows the results of ChIP assays in which a with FK317 but were produced when the cells were
specific anti-HMGA1 antibody was used for probing the nonspecifically crosslinked with formaldehyde (data not
shown). We conclude from these data that FK317 cross-
links HMGA1 proteins to the minor groove of promoter
regions of the IL-2 and IL-2R genes in Jurkat cells in
vivo. Crosslinking proteins to the DNA minor groove
is, therefore, a general property of FR900482 and its
derivatives and represents a novel mode of action for
this class of chemotherapeutic drugs.
Apoptosis versus Necrosis: Differential Effects
of FK317 and FR900482
The two most thoroughly characterized modes of cell
death are apoptosis and necrosis. Both pathways can
be triggered by a wide variety of factors and lead to the
same end—total cell degeneration. There are markedFigure 3. Agarose Gel Electrophoretic Separation of PCR-Amplified
differences, however, in both the morphological charac-DNA Products Derived from ChIP Assays of the IL-2 and IL-2R
Gene Promoters in Jurkat Cells Treated with FK317 by the Use of teristics and the cellular pathways involved in the two
an Anti-HMGA1 Specific Antibody modes of death. For example, apoptosis usually occurs
(A) PCR reactions performed on the pellets of the IL-2R promoter in single cells and rarely do all the cells in one area of
ChIP assays. Lanes are as follows: (4) control (i.e., non-drug-treated) an organ or tissue undergo death at the same time,
Jurkat cells; (3) cells treated with 0.5 M FK317 for 24 hr; (2) control whereas necrotic cell death involves large groups of
(i.e., non-drug-treated) cells treated with formaldehyde, a nonspe-
cells and sometimes even entire organs or tissues. Fur-cific chemical crosslinking reagent; and (1) IL-2R promoter frag-
thermore, as shown in diagram A of Figure 4, one of thement amplified from naked Jurkat genomic DNA with the same PCR
primers as those employed in the IL-2R ChIP reactions (specific first detectable changes in a cell undergoing apoptosis,
size marker). as opposed to necrosis, is noticeable cytoplasmic
(B) PCR reactions performed on the pellets of the IL-2 promoter shrinkage (reviewed in [20]). This is soon followed by
ChIP assays. Lanes are as follows: (4) control (i.e., non-drug-treated) changes in intracellular Ca2 and ATP levels, loss of
Jurkat cells; (3) cells treated with 0.5 M FK317 for 24 hr; (2) control
mitochondrial membrane potential, and activation of(i.e., non-drug-treated) cells crosslinked with formaldehyde; and (1)
proteolytic caspases. Concomitant with these changes,IL-2R promoter fragment amplified from naked Jurkat genomic
DNA with the same PCR primers employed in the IL-2 ChIP reactions fragmentation of the nuclear DNA occurs (Figure 4A)
(specific-size marker). and is followed by reorientation of phosphatidylserine
(C) In lanes 2–4, PCR products were obtained from the supernatants from the inner to the outer surface of the cytoplasmic
of the same ChIP reactions shown in panel B. Using IL-2 primers membrane (Figure 4B). The cellular cytoplasm and de-
confirmed that all of the cellular extracts contained amplifiable DNA.
graded organelles finally bleb off into apoptotic bodies,In lane 1, a positive IL-2 size control fragment amplified from naked
and the cell degenerates (Figures 4C and 4D). Macro-DNA is shown. The lower of the two bands present in both panels
B and C are primer-dimer amplification artifacts. phages and other types of phagocytic cells target the
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Figure 4. A Schematic Diagram of Necrosis and Apoptosis Indicates when, during the Death Process, Cells Stain Positive for Annexin-V-FITC
and PI
Cells labeled A and B are in the early stage of apoptosis, whereas those labeled C and D are in the late stage. Cells labeled E are in the early
stage of necrosis, whereas those labeled F and G are in the late stage. Cells undergoing apoptosis fragment their DNA/chromatin and shrink
in size early during the death process (A). Also during the early stages of apoptosis, phosphatidyl serine, which is normally situated on the
inner surface of the cytoplasmic membrane, flips to the outside (B), and the cells become Annexin-V positive when stained with Annexin-V-
FITC. Subsequently, their membranes become permeable, the cells bleb off apoptotic bodies, and their DNA fluoresces red when stained
with propidium iodide (i.e., they become PI positive). Apoptotic cells at this late stage fluoresce both green and red and are TUNEL positive
when assayed for DNA fragmentation. In contrast, the early stages of necrotic cell death are characterized by the swelling of both the cytoplasm
and the nucleus of cells, as well as by marked chromatin condensation (E). As a consequence of the loss of cytoplasmic membrane integrity,
the DNA of early necrotic cells fluoresces red when the cells are stained with PI (E). Shortly afterwards, the cells begin to lose cytoplasm (F)
and finally become Annexin-V positive at the later stages of the necrosis process, producing cell fragments that fluoresce both red and
green (G).
apoptotic cell remnants after detecting changes in these the drug concentration employed [13]. However, for a
chemotherapeutic agent, an apoptotic mode of cellcells’ outer cytoplasmic membrane. The phagocytes en-
gulf and degrade the apoptotic debris of individual cells death is preferred because necrosis sometimes leads
to severe inflammation and serious side effects suchand thus prevent inflammation [21–24].
In contrast to apoptosis, the early morphological as VLS. We were therefore interested in determining
whether the FK317 derivative of the FR900482 drug alsoevents that accompany cellular death by necrosis are
cytoplasmic and nuclear enlargement and condensation caused necrosis or if the structural difference(s) altered
its biological action and mode of cell death.of chromatin (Figure 4E). There is also a rapid loss of
the integrity of the cytoplasmic membrane (Figures 4E Flow cytometry using fluorescein-isothiocyanate
(FITC)-labeled Annexin-V and propidium iodide (PI)and 4F) and an eventual loss of cytoplasm into the extra-
cellular space (Figure 4F). This loss of cytoplasm is the allows one to experimentally distinguish among early
apoptotic, early necrotic, and late apoptotic/late ne-result of cations moving from the interior to the exterior
of the cell. As a consequence of this cation flux and other crotic events (c.f., Figure 4). Cells that are undergoing
apoptosis “flip” phosptidylserine from the inside to thepathological changes, extracellular fluids enter into the
cell and cause it to swell and eventually rupture into outside of the cytoplasmic membrane leaflet early in the
death pathway (Figure 4B), which allows Annexin-V, afragments (Figure 4G) that are engulfed and degraded
by phagocytes. Due to the loss of cytoplasm into the natural substrate of phosphatidyl serine, to bind to the
outer membrane of the cells. Thus, in time-course stain-extracellular space and to the fact that large numbers
of cells usually undergo simultaneous degeneration in ing experiments, cells undergoing apoptotic death will
first stain with Annexin-FITC and fluoresce green whenthe same localized area of an organ or tissue, inflamma-
tion usually accompanies necrotic cell death [21–24]. analyzed by a flow cytometer. Only at later stages of
the death process, when the cytoplasmic membraneWe have previously demonstrated that FR900482 in-
duces necrotic cell death in Jurkat cells regardless of becomes permeable, will apoptotic cells fluoresce red
Different Biological Effects of FK317 and FR900482
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as a result of PI binding to DNA (Figure 4D). A reverse the FK317 drug induces cellular necrosis. In marked
contrast, cells treated with 10 M FK317 for 24 hr (panelsequence of fluorescence staining events is observed
for cells undergoing necrosis. Early during necrosis, G) and 72 hr (panel H) first shift to the lower-right quad-
rant and then to the upper-right quadrant, indicatingcells first stain red with PI as a consequence of early
membrane permeability changes (Figure 4E) and only that at a 10-fold higher concentration the drug induces
changes characteristic of apoptotic cell death. Likewise,later stain green with Annexin-V-FITC as a result of the
exposure of phosphatidyl serine on the outer surface of the FK317 drug also induces apoptotic cell death at
even higher drug concentrations (e.g., 100 M; Figuresthe cytoplasmic membrane (Figure 4G; [25, 26]).
As schematically shown in Figure 5A, the readout of 5I–5K; unpublished data).
In order to better compare the responses of Jurkatfluorescence intensities from flow cytometric analyses
employing Annexin-V-FITC/PI double staining of cells cells exposed to different concentrations of FR900482
and FK317 drugs, we performed flow-cytometric analy-in time-course experiments can be used to determine
whether drug treatments induce apoptotic or necrotic ses in triplicate and graphed the percentage of cells
found in each quadrant as a function of time of drugcell death. In this diagram, increasing intensity of green
Annexin-V-FITC fluorescence is plotted on the hori- treatment (Figures 5I–5K). These experiments demon-
strated that the percent of cells staining as early necroticzontal (x) axis, and increasing intensity of red PI fluores-
cence is plotted on the vertical (y) axis. Thus, in flow (i.e., upper-left quadrant) was high for cells treated with
either 1 M FK317 or 10 M FR900482 (panel I), as wellcytometric experiments, viable (i.e., untreated, control)
cells will exhibit little red or green fluorescence and as all other concentrations of the FR drug used (data
not shown). In contrast, the percent of apoptotic cellswill cluster in the lower left-hand quadrant of the flow
cytometry screen, whereas drug-treated cells undergo- after treatment with either 1 M FK317 or 10 M
FR900482 was low (panel J). From these graphs it ising early necrosis will exhibit increased relative amounts
of red:green fluorescence and will cluster in the upper also evident that for cells treated with 1 M FK317 the
percent of early necrotic cells decreased with timeleft-hand quadrant of the screen (Figure 5A). Corre-
spondingly, early apoptotic cells will cluster in the lower (panel I). This decrease in the percent of necrotic cells
can be accounted for by a corresponding increase inright-hand portion of the flow cytometry screen because
of increased green:red fluorescence, and both late ne- the percent of late necrotic/late apoptotic cells at later
time points (panel K). In contrast, cells treated with 10crotic and late apoptotic cells will cluster in the upper
right-hand quadrant of the screen (Figure 5A). The num- M FR900482 did not exhibit changes in their percent
necrotic death over time (panels I and K). Most signifi-bers of cells (each dot represents one cell) in the different
flow-cytometric quadrants therefore represent the pro- cantly, however, it should be noted that the percent of
early necrotic cells was very low for both 10 and 100 Mportion of cells undergoing different modes of cell death
in a population. FK317 (panel J), whereas the percent of early apoptotic
cells at these drug concentrations was high (panel J).In time-course experiments to distinguish between
necrotic and apoptotic cell death, the FR900482 and These same drug-treated populations also exhibited an
increase in the percent of late necrotic/late apoptoticFK317 drugs were added to Jurkat cells at 1, 10, and
100 M concentrations and incubated for 24, 48, or 72 cells with time (panel K) while showing a decrease in
their percent of early apoptotic cells (panel J). Therefore,hr before flow-cytometric analysis. Quadrant settings
were determined for each experiment based on controls the cumulative data from these flow cytometric analyses
indicate that cells treated with high concentrations (10that were simultaneously run in parallel; therefore the
actual quadrant lines varied somewhat from experiment and 100M) of FK317 become more apoptotic with time,
whereas those treated with the lowest concentration (1to experiment (Figure 5). Regardless of the settings,
however, the results of these carefully controlled time- M) of this drug became more necrotic. Thus, a necro-
sis-to-apoptosis switch occurs in Jurkat cells treatedcourse experiments reproducibly demonstrated that
Jurkat cells treated with FR900482 first increased their with different concentrations of the FK317, but not the
FR900482, drug.red PI staining intensity and only later became positive
for green Annexin-V-FITC staining (data not shown), thus As an independent method for verifying the flow cyto-
metric data, drug-treated cells were double-stained withconfirming our earlier observations that this drug in-
duces necrotic cell death in a concentration-indepen- hematoxylin and Giemsa, and their morphology (c.f.,
Figure 4) was examined for features that are characteris-dent manner [13]. In contrast, as illustrated by the repre-
sentative flow-cytometric analyses shown in panels B–H tic of either necrosis or apoptosis (Figure 6). In compari-
son to untreated Jurkat cells (Figure 6J), cells treatedof Figure 5, the mode of death induced by the treatment
of Jurkat cells with FK317 depends on the drug concen- with 1 M FK317 (Figures 6A–6C) or 1 M FR900482
(see Figure 5 of reference [13]) became enlarged, losttration employed. For example, in comparison to un-
treated controls (panel B), after 24 hr of treatment with cytoplasmic integrity, and underwent nuclear condensa-
tion. These morphological changes are indicative of a1 M of FK317, a significant fraction of the Jurkat cells
had increased their relative PI red fluorescence intensity necrotic mode of cell death. In contrast, Jurkat cells
treated with either 10 or 100 M FK317 (Figures 6D–6I)as indicated by their shift to the upper-left quadrant
(panel E), whereas at a later time (72 hr) they had in- exhibited nuclear fragmentation (panel D) and the forma-
tion of apoptotic bodies (panels E–I), morphological fea-creased both their red and green intensities and shifted
to the upper-right quadrant (panel F). This characteristic tures characteristic of death by apoptosis. The results
from two independent experimental methods, flow-time course of changes in relative red:green fluores-
cence intensities indicates that at low concentrations cytometric analysis and cytological examination, are
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Figure 5. Flow Cytometric Analysis of Jurkat Cells Treated with Various Concentrations of FK317 and Stained with Annexin-V-FITC and PI
Annexin-V-FITC staining appears as green fluorescence, and PI staining appears as red fluorescence. Panel (A) shows a schematic of a flow
cytometry grid indicating into which quadrant cells that are viable, early necrotic, early apoptotic, or late apoptotic/late necrotic would fall
(see text for discussion). Arrows depict increasing red (y axis) or green (x axis) fluorescence. Panels (B–H) show representative flow-cytometric
analyses (the data in each panel are derived from an independent, appropriately controlled experiment) of cells that were treated with different
concentrations of FK317 for different periods of time. Each panel shows a representative analysis based on at least three separate experiments.
The numbers in each quadrant indicate the percentage of cells in the population in that quadrant. Jurkat cells were (B) left untreated (i.e., no
drug control); (C) treated with 10% EtOH (an inducer of necrosis) for 10 min; (D) treated with 1 M mitomycin C (an inducer of apoptosis) for
72 hr; (E) treated with 1 M FK317 for 24 hr or (F) for 72 hr; or (G) treated with 10 M FK317 for 24 hr or (H) 72 hr. Panels (J–K) are Excel-
derived graphs of these flow cytometry results and show the percentage of cells present in each quadrant as a function of both drug
concentration and time of treatment. Panel I shows the percent of early necrotic cells, panel J shows the percent of early apoptotic cells,
and panel K shows the percent of late necrotic/late apoptotic cells. It should be noted that, regardless of the time of treatment, at a concentration
of 1 M of FK317 and 10 M of FR900482 the percent of early necrotic cells was relatively high, whereas the percent of early apoptotic cells
was very low. In contrast, for cells treated with either 10 M or 100 M FK317, the percent of necrotic cells was very low, whereas the percent
of apoptotic cells was high. As discussed in the text, these results indicate that at low concentrations the FK317 drug preferentially induces
necrotic cell death, whereas at high concentrations it induces apoptosis.
therefore in agreement and indicate that, whereas for determining the mode of cell death, the TUNEL assay.
The TUNEL assay involves the in situ addition of fluores-FR900482 induces necrosis in Jurkat cells at all concen-
trations tested, the FK317 drug causes a concentration- cently labeled deoxyuridine triphosphate (dUTP) to the
free ends of damaged DNA in the nuclei of permeabilizeddependent switch from necrosis to apoptosis.
To further investigate the validity of these unantici- cells by the use of the enzyme terminal deoxynucleotidyl
transferase (see Experimental Procedures). Therefore,pated results, we employed a third widely used method
Different Biological Effects of FK317 and FR900482
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Figure 6. Cytological Confirmation of the Dose-Dependent Effects of FK317 on the Induction of Cellular Necrosis and Apoptosis
Gross morphology (100 magnification) of Jurkat cells treated with 1 M (A–C), 10 M (D–F), or 100 M (G–I) of FK317 for 24 (A, D, and G),
48 (B, E, and H), or 72 (C, F, and I) hr and double-stained with hemotoxylin (purple; nucleus) and Giemsa (blue; cytoplasm). Panel J shows
untreated cells. Cells treated with 1M FK317 (A–C) first become swollen, undergo nuclear chromatin condensation, and then loose cytoplasmic
integrity, indicating that they are undergoing necrosis. Those cells treated with 10 (D–F) and 100 (G–I)M FK317 exhibit chromatin fragmentation
(D) and have formed apoptotic bodies (E–I), indicating that they are undergoing apoptosis. The gross morphology of Bcl-2-overexpressing
Jurkat cells that have been treated with 100 M FK317 for either 24 (K) or 72 (L) hr demonstrates that such cells first become swollen and
then lose their cytoplasmic integrity in a manner similar to that of Jurkat cells that are undergoing necrotic cell death after treatment with 1
M FK317 (A–C).
the nuclei of cells undergoing DNA fragmentation as a (effector) caspases 3 and 7, fluoresces red when cleaved
by proteolysis. This increased red fluorescence, whichconsequence of apoptosis are fluorescently labeled in
TUNEL assays, whereas those undergoing death by ne- is indicative of the activation of cellular apoptosis, is
easily detected and measured by flow cytometry (seecrosis are not. Importantly, in comparison to the
Annexin-V-FITC assay, which detects the early stages Experimental Procedures). The flow cytometry results
shown in Figure 7 demonstrate that neither cells treatedof apoptosis, TUNEL assays detect only the late DNA
fragmentation events associated with apoptosis (c.f., with 1 or 10 M of FR900482 (panels D and E) nor
those treated with 1 M of FK317 (panel B) exhibitedFigure 4); thus, the two methods represent complemen-
tary ways of assessing apoptotic cell death. TUNEL red fluorescence above the background observed in
control Jurkat cells that have not been exposed to drugsassays were performed on Jurkat cells treated with 1
M, 10M, and 100M FK317 for 24 hr and, as expected (panel A). In contrast, Jurkat cells treated with 10 M
FK317 (panel C) exhibited a marked increase in red fluo-from our earlier findings, the nuclei of cells treated with
1 M were not labeled by the enzymatic incorporation rescence, as indicated by the shift of a significant num-
ber of cells into the area marked M1 in the flow diagram.of fluorescent dUTP, whereas those treated with 10 and
100 M were (data not shown). These results indicate These data clearly indicate that apoptosis-inducing cas-
pases have been activated in cells treated for 24 hr withthat, in agreement with both the Annexin-V-FITC data
and the cellular morphology data, Jurkat cells treated 10 M FK317 but not (as expected for necrotic cells) in
cells treated with either 10 M FR900482 or 1 M FK317with 10M and 100M FK317 undergo an apoptotic cell
death, whereas those treated with 1 M FK317 do not. for the same time period.
In the context of chemotherapeutic agents, necrosisAs a final approach to assessing the mode of death
in drug-treated cells, we performed experiments to de- is generally thought to be the consequence of acute
cellular toxicity, and an apoptosis-to-necrosis switch istermine whether the caspase proteolysis cascade is ac-
tivated in cells treated with either FK317 or FR900482. often observed when one goes from lower to higher
concentrations of drugs. Therefore, the switch in theCaspase activation is an apoptotic-cell characteristic
that occurs sometime between when dying cells be- opposite direction, from necrosis-to-apoptosis, that we
observed with the FK317 drug was unexpected and ini-come Annexin-V-FITC positive and when they become
TUNEL positive (c.f., Figure 4). Jurkat cells were treated tially surprising, but not unprecedented. Recently, Pa-
lomba et al. [27] found a similar necrosis-to-apoptosisfor 24 hr with 1 or 10 M of either FK317 or FR900482,
collected by centrifugation, and then resuspended and switch when U937 cells were treated with H2O2 and the
poly (ADP-ribose) polymerase (PARP) inhibitor 3-amino-incubated in a buffer containing the dye Phi Phi Lux.
Phi Phi Lux, a peptide substrate for the downstream benzamide (3AB). These authors found that when U937
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Figure 8. Northern Blot Analysis of mRNA Isolated from FK317- and
FR900482-Treated Jurkat Cells with Bcl-2 and Gapdh cDNAs as
Hybridization Probes
(A) Bcl-2 probe; (B) Gapdh probe. RNA was isolated from Jurkat
cells that were treated with 1 M FR900482 (lane 1), 100 M
FR900482 (lane 2), 1 M FK317 (lane 3), 10 M FK317 (lane 4), or
100 M FK317 (lane 5) or left untreated (lane 6). The cells were
then separated by electrophoresis on a formaldehyde agarose gel,
transferred to a nylon membrane, and probed by hybridization. It
should be noted that Bcl-2 message (A) is high in cells treated with
1 and 100 M FR900482 (lanes 1 and 2), decreased in those cells
treated with 1 M FK317 (lane 3), and is undetectable in cells treated
with 10 and 100 M FK317 (lanes 4 and 5) as well as in untreated
control cells (lane 6). The levels of Gapdh message remained essen-
tially constant in both control cells and cells treated with various
concentrations of drugs (B).
teins, and function [22]. Effectors of this permeabilityFigure 7. Induction of Apoptosis Effector Caspases 3 and 7 in Cells
Treated with FK317 include ions, nucleotides, and lipids, all of whose levels
Jurkat cells were either left untreated (A) or treated for 24 hr with 1 change markedly during apoptosis or necrosis [22, 30].
M (B) or 10 M (C) FK317 or with 1 M (D) or 10 M (E) FR90082. When this transition causes bioenergetic and redox
The cells were then incubated with the peptide Phi Phi Lux, a sub- changes, necrosis is induced, but when it causes the
strate for the downstream effector caspases 3 and 7 that fluoresces release of cytochrome C, Apoptosis-Inducing Factor
upon proteolytic cleavage, and the treated cells were analyzed by
(AIF), and other death-inducing factors, apoptosis re-flow cytometry. It should be noted that, as demonstrated by the
sults [22, 24]. It therefore seems reasonable, if one as-shift of cells into the area marked M1, a significant number of cells
treated with 10 M FK317 exhibit increased red fluorescence (C) sumes that a necrotic cell death pathway does exist in
indicative of the activation of apoptosis-inducing caspases within all cells, that a “switch” could easily occur during the
24 hr of drug treatment. The placement of M1 was determined by death initiation process to direct a cell toward either
the negative control (A). necrosis or apoptosis, depending on which proteins and
other stimuli are associated with the mitochondria per-
meability transition.
cells were treated with a constant amount of 3AB and
increasing concentrations H2O2, cellular necrosis oc- Bcl-2 Proteins and the Necrosis-to-Apoptosis
curred at low hydrogen peroxide concentrations, whereas Switch
apoptosis occurred at higher concentrations. Treatment A possible explanation for the necrosis-to-apoptosis
of cells with 3AB alone did not induce apoptosis. From switch we observed is that cellular levels of the anti-
these data, Palomba and colleagues concluded that an apoptotic protein Bcl-2 change depending on drug con-
active necrotic cell death pathway exists in U937 cells centration. The Bcl-2 proteins are major players in de-
and that this pathway is modulated by the inhibitor 3AB. termining which mode of cell death the mitochondrial
They also hypothesized that an active necrotic death permeability transition causes. Additionally, in Jurkat
pathway exists in other cell types, as well. cells it has been demonstrated that mitochondria are
The argument for a necrotic cell death pathway is required for the activation of downstream caspases dur-
made stronger by the facts that cellular mechanisms ing apoptosis activation and also that Bcl-2 can inhibit
that signal either early necrosis or apoptosis overlap and apoptosis [31]. Members of the Bcl-2 protein family (in-
that it is only due to slight fluctuations in one direction or cluding Bcl-2, Bax, Bcl-x, Bak, Bad, and MCl-2) have
the other that leads to either apoptosis or necrosis [28, the ability to homodimerize, to heterodimerize with other
29]. One such mechanism is the mitochondria perme- members of the Bcl-2 family, and also to bind to other
ability transition. It has been argued that similar changes nonhomologous proteins. The biological function of
relating to the mitochondria permeability transition oc- Bcl-2 complexes is dependent on their composition and
cur in both early necrosis and early apoptosis [22]. This influences—for example, the formation of ion channels
transition involves the formation of regulated mega- and pores [32]. Overexpression of Bcl-2 inhibits the ef-
channels within a dynamic ensemble of proteins that flux of cytochrome C from mitochondria and thereby
cross both the inner and outer membranes of the mito- prevents apoptosis [24]. This, in turn, preserves caspase
chondria. The opening of this channel during apoptosis 3 in its inactive state and thereby prevents the cleavage
causes the release of solutes that are larger than 1500 of death pathway substrates and the downstream mo-
lecular cascade that leads to apoptosis [33]. This inhibi-kDa and results in the loss of mitochondrial RNA, pro-
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Figure 9. Growth Characteristics of Bcl-2-Overexpressing Jurkat Cells Treated with Various Concentrations of the FK317 Drug
The number of cells in the various cultures was manually determined by hemacytometer counting. The arrow indicates the point at which
drug (0, 1, 10, or 100 M) was added to cultures (i.e., at 24 hr after subculturing of the cells).
tion of apoptosis has been shown to be due to the between the cellular levels of Bcl-2 protein and the levels
of Bcl-2 mRNA [37, 38]. Therefore, it is likely that theformation of Bcl-2 homodimers in cells. In contrast,
when Bcl-2 forms hetereodimers with other proteins, mRNA increase we observe here directly leads to in-
creasing amounts of Bcl-2 protein in the drug-treatedsuch as Bax, it promotes apoptosis [34]. Therefore, the
ratio of Bcl-2 homodimers to hetereodimers plays an cells. In addition, a correlation between increased levels
of Bcl-2 mRNA and decreased apoptosis has been dem-important role in the determining whether apoptosis or
necrosis occurs. High cellular levels of Bcl-2 lead to the onstrated [39]. In light of these data, it can therefore be
hypothesized that in cells treated with various concen-formation of more homodimers, which in turn results in
the inhibition of apoptosis [32, 35, 36, 33]. In contrast, trations of FR900482 or with low levels of FK317, the
Bcl-2 homodimer/hetereodimer ratio is high and that itat low cellular levels of Bcl-2, this ratio is likely to de-
crease and thereby promote apoptosis. is this elevated ratio that is preventing cells from under-
going apoptosis. Nevertheless, it is also likely that theseTo investigate whether Bcl-2 proteins participate in
the differential effects of the FR900482 and FK317 drugs same drug-treated cells have accumulated enough
damage as a consequence of drug-induced DNA-pro-on Jurkat cells, we isolated mRNA from drug-treated
cells and probed them by Northern blot analysis for tein and/or DNA-DNA crosslinks that necrotic death is
triggered. A finding consistent with this hypothesis isBcl-2 message. The cDNA probe for Bcl-2 used in these
experiments was specific for both Bcl-2 and its trun- the fact that, as shown in Figure 8A, cells treated with
higher concentrations of FK317 (10 M, lane 3; 100 M,cated isoform, Bcl-2, but did not detect any other mem-
bers of the Bcl-2 family. However, owing to its size, the lane 4) have undetectable levels of Bcl-2 mRNA. This
suggests that in cells treated with these higher FK317band observed on Northern blots corresponds to the
Bcl-2 isoform and not to the isoform (data not shown). concentrations, the endogenous Bcl-2 homodimer/het-
ereodimer ratio is considerably lower than in cellsThus, when we refer to Bcl-2 we mean the  isoform.
As shown in Figure 8, the levels of Bcl-2 mRNA differed treated with FR900482 (or low levels of FK317), thereby
causing signals such as cytochrome C and AIF to bemarkedly between cells treated for 24 hr with FR900482
and those treated with FK317. FR900482-treated cells released from mitochondria that induce apoptotic cell
death.had the highest levels of Bcl-2 message (Figure 8A,
lanes 1 and 2), whereas the Bcl-2 message levels in cells To further investigate the possible involvement of
Bcl-2 in the necrotic/apoptotic switch induced bytreated with 1 M FK317 were considerably reduced
(Figure 8A, lane 3) and were undetectable in cells treated FK317, we investigated drug-induced cell death in trans-
genic Jurkat cells that were overexpressing the Bcl-2with either 10 or 100 M FK317 (Figure 8A, lane 4–5).
In comparison to untreated Jurkat cells (Figure 8A, lane protein (Jurkat-Bcl2 cells) [40]. If, as speculated, the
cellular levels of Bcl-2 protein are indeed mechanisti-6), cells treated with all concentrations of FR900482 or
with 1 M FK317 had higher levels of Bcl-2 expression. cally associated with the necrosis-to-apoptosis switch,
a difference in the mode of cell death and/or detectableThe levels of mRNA of a control housekeeping gene,
Gapdh, remained constant in all of the cells (Figure 8B), changes in the degree of cellular toxicity would be pre-
dicted for Jurkat-Bcl2 cells, compared to the parentaldemonstrating that equal amounts of mRNA were ana-
lyzed in these experiments. It should be stressed that Jurkat cells, that are treated with increasing concentra-
tions of FK317. To determine whether such altered cellu-several recent papers have shown a direct correlation
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lar responses are observable, we used growth curves
to compare the proliferation rates of both the Jurkat and
Jurkat-Bcl2 cells in the presence of 1, 10, and 100 M
of either FK317 or FR900482 (Figure 9 and data not
shown). As anticipated, no differences were observed
between the growth rates of the Jurkat and Jurkat-Bcl2
cells that were treated with FR900482 because this drug
induced necrotic death at all of the concentrations used
(data not shown). In contrast, Jurkat-Bcl2 cells that were
treated with higher concentrations of FK317 (10 and 100
M) exhibited noticeably greater proliferative capacity
than the parental Jurkat cells at each of the drug concen-
trations (Figure 9). Trypan blue dye exclusion viability
assays also indicated that the drug-treated Jurkat-Bcl2
cells died at a somewhat slower rate than the normal
Jurkat cells at high drug concentrations (data not
shown), suggesting that they were somehow “pro-
tected” from FK317-induced cell death. It is reasonable
to speculate that the increased levels of Bcl-2 protein
present in the Jurkat-Bcl2 cells provided this “protec-
tion” by inhibiting the apoptotic death pathway and thus
forcing the cells to die by necrosis. To confirm that, in
this case, such a switch between drug-induced apopto- Figure 10. Northern and Western Blot Analyses of FK317- and
sis and necrosis did occur in these cells, we examined FR900482-Treated Jurkat Cells with, respectively, either IL-2R,
IL-2, or Gapdh Hybridization Probes or Anti-IL-2R Antibodythe morphology of Jurkat-Bcl2 cells that had been
(A) Northern blot. RNA was isolated from Jurkat cells treated withtreated with 1, 10, or 100 M FK317 and stained with
1 M FR900482 (lanes 3–5) or 1 M FK317 (lanes 6–8) for 6 hr (laneshemetoxylin and Giemsa (Figures 6K and 6L and data
3 and 6), 12 hr (lanes 4 and 7), or 24 hr (lanes 5 and 8). For negativenot shown). The overall morphology of these drug-
and positive controls of IL-2 and IL-2R mRNA induction, Jurkat
treated cells had clearly changed from that of apoptotic cells were, respectively, left untreated (lane 2) or treated with a
cells (Figures 6D–6I) to that of necrotic cells, as demon- combination of PMA/Con A for 24 hr (lane 1). RNA was isolated and
strated by the fact that by 24 hr of drug treatment they analyzed as in Figure 8 except that probes for the Il-2R (exon 1),
Il-2 (3 UTR), and Gapdh cDNA were used.had become noticeably swollen (Figure 6K) and by 72 hr
(B) Western blot analysis of total proteins isolated from either un-had lost their cytoplasmic integrity (Figure 6L). Together,
treated Jurkat cells (lane 1) or cells treated with 1 M FK317 (lanethese data are consistent with the proposal that Bcl-2
2), 1 M FR900482 (lane 3), or a combination of PMA/Con A (lane
plays an important role in determining the mode of cell 4). The gel in the top of panel B was stained with Coomassie blue
death and in inducing the necrotic/apoptotic switch and demonstrates equal protein loading in all of the lanes. The lane
caused by FK317. Furthermore, the results provide a labeled MW on the right contains standard molecular-weight protein
markers (sizes in kDa are indicated on the side) for comparison.cautionary note that the concentrations of FK317 drug
The lower part of panel B shows a Western blot of a portion of aemployed for cancer therapeutic purposes should be
gel, identical to that shown above, reacted with a specific anti-IL-optimized to ensure the induction of apoptotic, rather
2R antibody. Note that FK317-treated cells (lane 2) contain approxi-
than necrotic, death of tumor cells. mately the same amount of IL-2R protein as untreated control cells
(lane 1), whereas FR900482-treated cells (lane 3) contain greatly
increased levels of protein—more, even, than Jurkat cells stimulated
Differential Drug-Induction of IL-2 with the potent IL-2R protein-inducing combination Con A/PMA
(lane 4).and IL-2R mRNAs
Early in our investigations we suspected that the pre-
viously discussed differential induction of VLS by
FR900482, but not by FK317, was likely to be mediated induces VLS, and FK317 doesn’t, is that only FR900482
induces the expression of IL-2.by mechanisms or factors other than the differences in
the modes of cell death caused by the two drugs. One To test this hypothesis, we performed Northern blot
analyses to determine the IL-2 and IL-2R mRNA levelspossibility, for example, would be for the two drugs to
differentially affect the expression of cytokines, such as present in cells treated with 1M of either the FR900482
or the FK317 drug for 6, 12, and 24 hr to compare theIL-2, that others have directly linked to the induction of
VLS [3]. Supportive of this idea is the fact that when levels of these messages found in untreated control
cells. As a positive control for these experiments, mRNAIL-2 adjuvant therapy was first used for cancer treat-
ment, VLS was a major detrimental side effect [3, 41]. was also isolated from cells that were treated with phor-
bol 12-myristate 13-acetate (PMA) plus concanavalin AThe induction of VLS by IL-2 treatment has been sug-
gested to be a consequence of IL-2 activation of the (Con A), a combination of stimulatory agents known to
induce transcription of the IL-2 and IL-2R genes inadherence of neutrophils to endothelial cells and the
release of reactive oxygen intermediates and proteases Jurkat cells [43]. Results of these Northern hybridization
experiments are shown in Figure 10A. In FR900482-from the bound neurtrophils that initiate lysis of the
endothelial cells [3, 42]. Based on this proposed sce- treated cells, the levels of both IL-2 (lanes 3–5) and IL-
2R (lanes 3–5) mRNAs increased markedly in responsenario, a reasonable hypothesis to explain why FR900482
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Figure 11. Flow-Cytometric Analyses of the Effects of Drug Treatment on the Time Course of Appearance of IL-2R Protein on the Cell Surface
(A) Jurkat cells were treated with either PMA/I alone, with FK317 (1 M) alone, or with a combination of PMA/I plus FK317 PMA (1 M).
(B) Jurkat cells were treated with either FR900482 (1 M) alone or with a combination of PMA/I plus FR900482 (1 M). At various time points
(0, 8, 12, 18, and 24 hr) after the initiation of an experiment, cells were probed for the presence of surface IL-2R protein by reaction with an
anti-IL-2R antibody labeled with the red-fluorescing dye phytoeryothrin (PE), and antibody binding was assessed by flow cytometry. An
increase in red fluorscence (in the region marked M1) is indicative of increased IL-2R protein on the outer surface of the cytoplasmic
membrane.
(C) Control experiments showing that both unstained Jurkat cells and Jurkat cells fixed immediately after antibody addition (0 hr samples)
have an intrinsic, naturally occurring red fluorescence whose peak lies to the left of the M1 region characteristic of surface-fluorescing IL-
2R protein. As discussed in the text, these results demonstrate two important points, namely that (1) the FR900482 drug alone (but not the
FK317 drug alone) induces the appearance of IL-2R protein on the cell surface and (2) the FK317 drug does not inhibit the PMA/I-induced
appearance of IL-2R protein on the cell surface.
to drug treatment and were similar to levels found in 10B). As is evident from the Western blot, the level of
IL-2R protein in cells treated with 1 M FK317 (lane 2)cells treated with a combination of PMA and Con A (lane
1) to induce transcription of these genes. On the other was similar to that in untreated Jurkat cells (lane 1). On
the other hand, cells treated with 1 M FR900482 (lanehand, the levels of IL-2 and IL-2RmRNAs did not signif-
icantly increase in cells treated with 1 M FK317 (lanes 3) contained even higher levels of IL-2R protein than
cells treated with the strong inducing combination PMA/6–8, in each row) and remained similar to those found
in untreated control cells (lane 2). Importantly, the levels Con A (lane 4).
Because surface expression of the IL-2R protein isof Gapdh, a control housekeeping gene, remained con-
stant regardless of the treatments (Figure 10A). required for the formation of a functional high-affinity
IL-2 receptor in activated lymphocytes, it was of consid-Western blot analysis was performed to investigate
whether the observed FR900482-induced increase of erable importance to determine whether treatment with
the FR900482 or FK317 drugs influenced either the nor-IL-2R mRNA also reflected a parallel increase in IL-
2R protein production. For these experiments, equal mal cytoplasmic membrane localization and/or the time
of appearance of this protein on the surface of Jurkatamounts of protein from either control or drug-treated
cells were separated by SDS-PAGE gel electrophoresis cells that were activated by PMA/ionomycin (PMA/I)
simulation. We therefore conducted experiments (Figureand transferred to a nitrocellulose membrane (upper part
of Figure 10B). The membrane was then reacted with 11) employing an anti-IL-2R antibody labeled with the
red fluorescing dye phycoerythrin (PE) and flow-cytome-antibody against the IL-2R protein (lower part of Figure
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tric analyses to monitor the temporal appearance of are likely to be a common feature of most FR900482
derivatives. Nevertheless, here we report that the twosurface IL-2R protein on PMA/I-stimulated Jurkat cells
that were treated, or not, with FK317 (1M) or FR900482 drugs exhibit several important biological differences.
The first is a difference in the mode of cell death in-(1 M) over a 24 hr period. As shown in Figure 11C,
“unstained control” Jurkat cells that have never been duced by the two drugs. The type of cell death induced
by chemotherapeutic agents is important because aexposed to the anti-IL-2R-PE antibody exhibit an intrin-
sic background red fluorescence due to the presence necrotic cell death can lead to serious side effects
such as VLS, whereas apoptotic cell death is less detri-of the dye phenol red in the cell culture media, and this
level of endogenous background fluorescence didn’t mental. Earlier, we reported that FR900482 induces
necrotic cell death [13]. In contrast, we now reportappreciably change when “0 hr” experimental cells were
briefly exposed to the anti-IL-2R-PE antibody. How- that FK317 induces necrosis at low drug concentra-
tions and apoptosis at high concentrations. One possi-ever, as shown in Figure 11A, the number of Jurkat
cells expressing surface IL-2R protein increased as a ble explanation for this therapeutically beneficial ne-
crosis-apoptosis switch is that a change in the Bcl-2function of time after PMA/I stimulation, as evidenced by
the fact that their intensity of red fluorescence staining homodimer/heterodimer ratio occurs at higher FK317
drug concentrations. The second important biologicalincreased (in the region marked “M1” in the cytometric
histograms) as a result of anti-IL-2R-PE antibody bind- difference between these two drugs is that FR900482,
but not FK317, induces both IL-2 and IL-2R geneing. These flow cytometry analyses indicate that IL-2R
protein first appears on the surface of cells less than 8 expression. The upregulation of IL-2 and IL-2R by
FR900482 could easily explain why FR900482 induceshr after PMA/I treatment (the earliest point analyzed)
and that by 12 hr post-stimulation many of the cells are VLS and FK317 does not. After metabolic processing
inside the cell, the active metabolites of FK317 andexpressing appreciable quantities of surface protein.
Furthermore, the results also show that the time course FR900482 differ by only one methyl group on the C5
phenolic oxygen atom. Given their noticeably differentof appearance of surface IL-2R protein in cells treated
with a combination of both PMA/I and FK317 was ap- biological effects, it will be informative to determine
whether the additional methyl group of FK317 man-proximately the same as that in cells treated with PMA/I
alone. Most interestingly, it is clear from these analyses dates significant structural differences in the way the
drugs crosslink proteins to the minor groove of DNA.that FK317 does not aberrantly induce the surface ex-
pression of IL-2R in unstimulated Jurkat cells, nor does
Experimental Proceduresit inhibit the surface induction of this protein in cells that
have been stimulated with PMA/I. In contrast, those cells
Cell Culturetreated with FR900482 alone (Figure 11B) did exhibit an
Human Jurkat T-leukemia cells (clone E6-1; American Type Culture
aberrant induction of the expression of surface IL-2R Collection, Rockville, MD) were grown in RPMI-1640 media (Gibco-
protein, but the drug had no noticeable effect on the BRL, Rockville, MD) supplemented with 5% Fetal Bovine Serum
induction of surface protein expression in cells treated (Atlanta Biologicals, Norcross GA), penicillin (614 ug/ml, Sigma, St.
Louis, MO), streptomycin (10 ug/ml, Sigma St. Louis, MO), andwith PMA/I.
HEPES buffer (pH 7.2) at 37	C and 5% CO2. Jurkat cells overexpress-The results from these various lines of investigation
ing Bcl-2 [40] were a generous gift from Dr. S.J. Korsmeyer andtherefore allow us to conclude that the FR900482 drug,
were maintained as for the Jurkat cells.
in contrast to FK317, upregulates the levels of expres-
sion of IL-2RmRNA in Jurkat cells which, in turn, leads Growth Inhibition and Viability Assays
to increased cellular concentrations and surface expres- Jurkat cells were plated at 5  106 cells per plate and grown for
sion of the IL-2R protein. In this connection, it is inter- 24 hr. Subsequently, FK317 was added at 0, 0.5, 1, and 1.5 M
concentrations. Cells were counted every 24 hr for the next 72 hresting to note that Li et al. [44] have recently reported
on a hemocytometer. Trypan Blue (2%) was added to the cells tothat necrotic cell death results in the upregulation of
determine cell viability. To determine the total number of live cells,NF-B, a transcription factor that is involved in the regu-
the number of blue cells (dead cells) was subtracted from the total
lation of both IL-2 and IL-2R genes, a finding that is number of cells. This number was then plotted as a function of time
consistent with our present results. It is tempting to with Excel.
speculate that the minor structural differences between
FR900482 and FK317, especially the presence of the Chromatin Immunopreciptation Assays (ChIP)
ChIP assays were done as previously reported [12]. In brief, 1  107methyl group on FK317, are responsible for the observed
Jurkat cells were left untreated, treated for 24 hr with 0.5 M FK317differences in their biological effects. The detailed
at 37	 and 5% CO2, or treated for 30 min with 1% formaldehydechemical mechanistic underpinning of this phenomenon
at room temperature. Cells were then harvested by centrifugation.is not presently understood and is the subject of ongoing
Nuclei were isolated with a buffer containing 0.34 M sucrose, 0.2
investigation. M KCl, 100 mM EGTA, 500 mM EDTA, 494 mM spermine, 689 mM
spermidine, 10 mM HEPES, and 5% NP-40. The nuclei were washed
in the same buffer without NP-40. The nuclei were then fragmented
by sonication to produce chromatin fragments containing, on aver-Significance
age, about 400–500 bp of DNA. The DNA was extracted by the
use of phenol:chloroform:isoamyl alcohol (25:24:1) and was ethanolThe FR900842 and FK317 drugs share several bio-
precipitated. The DNA was then subsequently redissolved in 1chemical and pharmacological properties, including
PBS, and HMGA1, Elf-1 (Santa Cruz Biotechnology, Santa Cruz, CA),
the ability to induce DNA-DNA interstrand crosslinks, or NF-B p50 (Santa Cruz Biotechnology, Santa Cruz CA) antibodies
minor-groove DNA-protein crosslinks, and similar (but were added at a 50:1 ratio. The reaction was allowed to proceed
overnight at 4	C, after which Protein A Sepharose beads (10:1) wereslightly different) cellular toxicities. These properties
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added. The DNA-protein crosslinks were then isolated by centrifuga- RNA was run out on a 6% formaldehyde, 1% agarose-MOPS gel
for 4.5 hr at 100 V. The RNA was transferred onto Superchargetion and collection of Protein A Sepharose beads. The beads were
then redissolved in 1 PBS and 5 g Proteinase K and incubated Nylon Membrane (Schleicher and Schuell, Keene, NH) in 20 SSC.
The blot was dried, rinsed in 5 SSC, and prehybridized in Per-overnight at 55	C. The DNA from the samples was extracted by the
use of phenol:choloroform:isoamyl alcohol (25:24:1). DNA was then fectHybPlus (Sigma, St. Louis, MO) and salmon sperm DNA (25 g/
ml) for 1 hr at 65	C. The processed membranes were hybridizedethanol precipitated and redissolved in water. PCR primer se-
quences for the IL gene promoter (accession number J006884) are with one or more of the following oligonucleotide probes derived
from human gene sequences: GAPDH (1200 bp cDNA, Genbankas follows: IL-2-1 (sense), 5-TAATGTAACAAGAGGGATTTC
ACC-3 (base pairs 193–217); and IL-2-2 (antisense), 5-GGAGTTGA accession number M33197); IL-2 (190 bp fragment from the gene
3 UTR, Genbank accession number M00586); IL-2Rr (220 bp frag-GGTTACTGTGAGTAGTC-3 (base pairs 450–427). PCR primer se-
quences for the IL-2R gene promoter (accession number M15864) ment from Exon 1, Genbank accession number M15864); and Bcl-2
(450 bp cDNA, Genbank accession number M000633). The hybrid-are as follows: IL-2R-1 (sense), 5-CCAGCCCACACCTCCAG
CAA-3 (base pairs 1052–1071); and IL-2R-2 (antisense), 5-CCTCT ization probes were 32P-radiolabeled by random priming procedures
as previously described [16], and in each reaction, approximatelyTTTTGGCATCGCGCCG-3 (base pairs 1306–1327). PCR conditions
were 0.5 mM dNTPs, 2 M primers, 4 mM MgCl2, 100 mM Tris (pH 10 ng/ml of 108 dpm/g probe was added to the prehybrization mix
incubated overnight at a hybridization temperature appropriate for9.0), 50 mM KCl, 1% Triton X-100, and 1 mM DTT. Taq polymerase
was used with 35 cycles of 96	C for 30 s, 58	C (IL-2R primers) or the probe. The hybridized blots were washed in 2 SSC and 0.1%
SDS for 10 min at room temperature, and phosphoimager anaylsis52	C (IL-2 primers) for 30 s, and 72	C for 45 s. The PCR samples
were run on a 1% agarose gel. was done (Molecular Dynamics, Sunnyvale, CA).
Mode of Cell Death Determination Western Blot Analysis
Jurkat cells (1  107 ) were treated with either 1, 10, or 100 M Jurkat cells were either treated with 1 M FK317, 1 M FR900482,
FK317 or 1, 10, or 100 M FR900482 (Fujisawa Pharmaceuticals) or both PMA (10 nM) and Con A (10 M) or left untreated for 24 hr.
for 24, 48, or 72 hr. Cells were then split into two separate groups Cells were then harvested by centrifugation, resuspended in SDS-
and pelleted by centrifugation. One group of cells was resuspended PAGE buffer (10% glycerol, 5% 2-mercaptoethanol, 10% SDS,
in 1 PBS and placed on poly-L-lysine (Sigma, St. Louis, MO)- 0.625 M Tris, and 0.1% bromophenol blue), and sonicated for 3
coated slides and fixed in formol alcohol (70% ethanol, 1.5% formal- min. Samples were heated to 95	C and placed immediately on ice.
dehyde, 1.5% acetic acid). Cells were stained in Gill’s Hemotoxylin Proteins were then separated by SDS-PAGE by the use of duplicate
and counterstained in Geimsa. The cells were then viewed with a 18% SDS-PAGE gels with a 3% SDS-PAGE stacking gel. Protein
compound microscope at 100 magnification. The other group of Molecular Weight Marker (Fermentas, Hanover MD) was used for
cells was used for flow cytometry analysis. Cells were treated with determination of molecular weights. One gel was transferred onto
Annexin-V-FITC (1:50 ratio, Caltag Laboratories, Burlingame, CA) in Immobilin-P membrane (Millipore, Bedford, MA) via the semidry
Annexin-V binding buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, transfer method by the use of transfer buffer (48 mM Tris, 39 mM
1 mM MgCl2, and 2.5 mM CaCl2) and incubated on ice for 10 min. glycine, 0.037% SDS, and 20% methanol). The transfer was allowed
The binding reaction was stopped by the addition of excess binding to proceed for 2 hr at 0.8 mA per cm2 of membrane. After transfer,
buffer. Propidium iodide (1:10 ratio of 1 mg /ml solution, Calbiochem, the membrane was wetted in methanol, rinsed in water, and blocked
La Jolla, CA) was added to the reaction, and flow cytometry analysis in PBS-T plus 1% dried milk. The membrane was then incubated
was performed with CellQuest (BD Biosciences, San Jose, CA). for 1 hr, and IL-2R antibody (Santa Cruz Biotechnology, Santa Cruz,
CA; 100:1) was added. The incubation then continued overnight. The
TUNEL Analysis membrane was rinsed extensively in 1 PBS-T. The membrane was
TUNEL assays were performed with the Apoptosis Detection Sys- then incubated in PBS-T plus 1% dried milk and goat antimouse
tem, Fluorescein kit (Promega, Madison, WI). In brief, Jurkat cells IgG HRP conjugate secondary antibody (BioRad Laboratories, Rich-
(3  107 ) were spread on a poly-L-lysine slide (Sigma, St. Louis, mond, CA) for 1 hr. The membrane was again rinsed extensively in
MO), washed in phosphate-buffered saline (PBS), fixed with 4% 1 PBS-T, after which chemiluminescence (Pierce, Rockford, IL)
paraformaldehyde, and permeabilized with 0.2% Triton X-100. The was performed to detect labeling. The second gel was stained in
cells were incubated with 50 M flourescein-12-dUTP, equilibration Coomassie blue stain (0.04% Coomassie brilliant blue, 10% acetic
buffer (supplied with the kit), and terminal deoxynucleotidyl trans- acid, and 25% isopropanol) for 1 hr and destained (10% methanol,
ferase (TdT) for 1 hr at 37	C. The reaction was stopped by washing 10% acetic acid, and 1% glycerol) overnight.
the cells in 2 SSC followed by washing twice in PBS. The cells
were counterstained with 1 mg/ml propidium iodine and washed in
Flow Cytometric Analysis of IL-2R on the Cell Surface
dH2O. The cells were analyzed with a fluorescence microscope. Jurkat cells (1  106 ) were treated with PMA (10 nM) and ionomycin
Cells that displayed green fluorescence were indicative of DNA frag-
(10 M) for 0, 1, 2, 4, 8, 12, 18, or 24 hr; treated with PMA (10 nM),
mentation due to labeling by fluorescein-12-dUTP by TdT.
ionomycin (10 M), and 1 M FK317 for 0, 1, 2, 4, 8, 12, 18 or 24
hr; treated with 1 M FK317 for 0, 1, 2, 4, 8, 12, 18, or 24 hr; or left
Caspase 3 and 7 Activation Assays untreated. Cells were pelleted after incubation, washed with 1
Jurkat cells (1  106 ) were either left untreated or treated with 1 or PBS, and incubated in 1 PBS and anti CD25-PE-labeled antibody
10 M of either FK317 or FR900482 for 24 hr. Cells were harvested (1:3, BD Pharmingen, San Jose, CA) on ice for 30 min. Cells were
and incubated with 5 l fetal bovine serum (Atlanta Biologicals, pelleted, washed with 1 PBS, and fixed in 2% paraformaldehyde.
Norcross, GA) and 50 l Phi Phi Lux (OncoImmunin, Inc, Gaithers- Flow-cytometric analysis was done with CellQuest (BD, Biosci-
burg, MD) for 1 hr at 37	C. After incubation was complete, the reac- ences, San Jose, CA).
tion was stopped by the addition of 1 ml flow cytometry buffer, and
cells were harvested. The cells were then resuspended in 1 ml flow
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solution, Calbiochem, La Jolla, CA). Flow-cytometric analysis was
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